Wednesday, April 15, 2026
wellness India Expo
Home Tags India

Tag: India

IAN Alpha Fund co-leads ₹70 Cr Series A funding round in...

The investment strengthens Peptris’ proposition as one of the leading Indian AI drug discovery platforms progressing beyond molecule generation towards clinical-ready assets

Illuminate 3.0: First of its kind consortium for clinical trials launched...

The event witnessed the launch of a book on Gastric cancer– an evidence-based diagnosis and treatment compilation

ISCR’s 19th annual conference focuses on the digital innovation shaping patient-centric...

The conference saw participation from more than 1900 individuals, with over 285 eminent speakers sharing their experiences

BioAsia 2026 positions Telangana as a global TechBio powerhouse

The mega life-sciences event is preparing to launch its 23rd edition on February 17–18. 2026

Syngene collaborates with Johns Hopkins University to advance early-stage drug discovery

The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research

Zydus Lifesciences reports strong Q3 and 9M FY26 financial performance

In Q3 FY26, revenue from operations rose 30% year-on-year to ₹68,645 million, while EBITDA grew 31% to ₹18,164 million, with margins improving to 26.5%

Pandorum Technologies raises US$18 Million in Series B to advance global...

Funding accelerates clinical development and market access across the U.S., Asia, and the Middle East

Novo Medi Sciences launches ‘G.A.U.R.I., a nationwide awareness movement for girl...

The missed-call awareness phase of G.A.U.R.I. (Generating Awareness on Underprivileged Girls’ Right to Immunization) will continue till 30th March 26, allowing sustained participation over several weeks

Rising cancer treatment costs and long care cycles increase financial exposure...

Early-stage treatment costs ₹5–7 lakh; complex cancer care can go up to ₹30 lakh

Zydus receives USFDA Orphan Drug Designation for Desidustat to treat Sickle...

Zydus’ NCE Desidustat is a hypoxia inducible factor (HIF)-prolyl hydroxylase inhibitor (PHI) and has the potential to increase haemoglobin and red blood cell counts